Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proviral genotype-guided dolutegravir plus lamivudine maintenance in virologically suppressed HIV-1 infection
2017-000151-10Phase 2Completed
- Sponsor
- FIBHULP
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dolutegravir and lamivudine in Human immunodeficiency virus infection type 1, sponsored by FIBHULP. Primary endpoint: Virological suppression at week 48. Started Jun 2017; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-000151-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000151-10.